Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial

被引:8
|
作者
Campillo, Jeremy T. [1 ]
Bikita, Paul [2 ]
Hemilembolo, Marlhand [2 ]
Louya, Frederic [2 ]
Missamou, Francois [2 ]
Pion, Sebastien D. S. [1 ]
Boussinesq, Michel [1 ]
Chesnais, CedricB [1 ]
机构
[1] Univ Montpellier, Inst Rech Developpement IRD, TransVIHMI, INSERM Unite 1175,UMI 233, Montpellier, France
[2] Ministere Sante & Populat, Programme Natl Lutte IOnchocercose, Direct IEpidemiol & Lutte Maladie, Brazzaville, Rep Congo
关键词
loiasis; clinical trial; levamisole; filariasis; Africa; WUCHERERIA-BANCROFTI; LOA; ONCHOCERCIASIS; ALBENDAZOLE; IVERMECTIN; CHEMOTHERAPY; PERIODICITY; AMODIAQUINE; MG;
D O I
10.1093/cid/ciab906
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Individuals with high microfilarial densities (MFDs) of Loa loa are at risk of developing serious adverse events (SAEs) after ivermectin treatment. Pretreatment with drugs progressively reducing Loa MFDs below the risk threshold might help prevent these SAEs. We assessed the safety and efficacy of levamisole for this purpose. Methods A double-blind, randomized, placebo-controlled, MFD-ascending trial was conducted in the Republic of the Congo. Participants were treated in 3 cohorts defined by pretreatment MFD and levamisole dose (cohort 1: 1.0kg and 1.5mg/kg; cohorts 2 and 3: 2.5mg/kg). Safety outcomes were occurrence of SAE and adverse event frequency during the first week. The efficacy outcomes were MFD reduction from baseline and proportions of individuals with at least 40% and 80% MFD reduction at day 2 (D2), D7, and D30. Results The 2 lowest doses (1.0mg/kg and 1.5mg/kg) caused no SAEs but were ineffective. Compared with placebo, 2.5mg/kg levamisole caused more mild adverse events (10/85 vs. 3/85, P=.018), a higher median reduction from baseline to D2 (-12.9% vs. +15.5%, P<.001), D7 (-4.9% vs. +18.7%, P<.001), and D30 (-0.5% vs. +13.5%, P=.036) and a higher percentage of participants with >40% MFD reduction at D2 (17.5% vs. 1.2%, P<.001), D7 (11.8% vs. 6.3%, P=.269), and D30 (18.5% vs. 9.6%, P=.107). Conclusions A single 2.5mg/kg levamisole dose induces a promising transient reduction in Loa loa MFDs and should encourage testing different regimens. Single dose of levamisole (2.5mg/kg) is safe in Loa loa-infected subjects and reduces microfilaremia temporarily. Higher doses or longer regimens should be tested to evaluate whether levamisole can be used as a pretreatment to prevent post-ivermectin Loa-related encephalopathy.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 50 条
  • [1] LEVAMISOLE IN CROHNS-DISEASE - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL-TRIAL
    SACHAR, DB
    RUBIN, KP
    GUMASTE, V
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1987, 82 (06): : 536 - 539
  • [2] The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
    McMurray, John J. V.
    Freeman, Mason W.
    Massaro, Joe
    Solomon, Scott
    Lock, Paul
    Riddle, Matthew C.
    Halvorsen, Yuan-Di C.
    [J]. DIABETES, 2020, 69
  • [3] Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
    Zhang, Junyan
    Yang, Xiaobin
    Chen, Guangui
    Hu, Jintao
    He, Ying
    Ma, Jinxiang
    Ma, Zhaoen
    Chen, Huifang
    Huang, Yuyi
    Wu, Qiurong
    Liu, Yongping
    Yu, Lu
    Zhang, Hong
    Lai, He
    Zhang, Jianguo
    Zhai, Jinming
    Huang, Minqi
    Zou, Zehong
    Tao, Ailin
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 132 (03)
  • [4] Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial
    Garbutt, James C.
    Kampov-Polevoy, Alexei B.
    Gallop, Robert
    Kalka-Juhl, Linda
    Flannery, Barbara A.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (11) : 1849 - 1857
  • [5] Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial
    Maria, Morais-Socorro
    Alvaro, Cavalcanti Maciel
    Rand, Martins
    Paulo, Neto Francisco
    Adriana, Rezende
    George, Azevedo
    Maria, Almeida
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (06) : 483 - 487
  • [6] ALBENDAZOLE IN HUMAN LOIASIS - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    KLION, AD
    MASSOUGBODJI, A
    HORTON, J
    EKOUE, S
    LANMASSO, T
    AHOUISSOU, NL
    NUTMAN, TB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (01): : 202 - 206
  • [7] Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
    Karbalaee, Monire
    Jameie, Melika
    Amanollahi, Mobina
    TaghaviZanjani, Fateme
    Parsaei, Mohammadamin
    Basti, Fatemeh A.
    Mokhtari, Saba
    Moradi, Kamyar
    Akhondzadeh, Shahin
    [J]. SCHIZOPHRENIA RESEARCH, 2023, 254 : 92 - 98
  • [8] Multicenter, randomized, double-blind, placebo-controlled, parallel trial comparing the safety and efficacy of rufinamide
    Biton, V
    Rosenfeld, W
    Schachter, S
    Perdomo, C
    Arroyo, S
    [J]. ANNALS OF NEUROLOGY, 2005, 58 : S114 - S114
  • [9] Efficacy and Safety of Vilazodone in Generalized Anxiety Disorder: A Randomized, Double-blind, Placebo-controlled Trial
    Thase, Michael E.
    Mathews, Maju
    Forero, Giovanna
    Nunez, Rene
    Chen, Changzheng
    Gommoll, Carl
    Durgam, Suresh
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S344 - S344
  • [10] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
    Ying Zhao
    Yuan-Yuan Yang
    Bao-Lin Yang
    Ya-Wei Du
    Da-Wei Ren
    Hong-Mei Zhou
    Jing Wang
    Hui-Min Yang
    Yao-Xian Wang
    Ying-Ying Zhang
    Sheng-Xian Wu
    [J]. Trials, 22